News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antisoma's Stock Falls On Phase III Miss With R1549


10/19/2005 5:11:05 PM

Antisoma plc's share price was halved Monday after the company announced its lead product, R1549, failed in a Phase III ovarian cancer trial - survival of R1549-treated patients was no better than patients in the comparative arm.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES